Senator Renews Scrutiny of Pharma Ties on Federal Panel
June 27, 2016
(New York Times) – A high-ranking Senate Democrat is pushing for more answers on why doctors and patient advocates with financial ties to the pharmaceutical industry came to serve on a panel that advises the federal government on pain issues. Sen. Ron Wyden says he is “even more concerned” about these apparent conflicts of interest after receiving a response from the National Institutes of Health, which vetted and selected the panel members. In a letter sent Thursday to the Obama administration’s top health official, Wyden requests a series of documents related to the pain panel, including financial disclosure forms filled out by its members.